When semaglutide hit the market as Ozempic and Wegovy, it became synonymous with weight loss—but inside the cells of millions of people, this drug was doing far more than trimming inches. Researchers have begun uncovering something that pushes the boundaries of what a single medication can do: GLP-1 agonists, a class of drugs that mimic a natural gut hormone, appear to offer protection against heart disease, liver damage, sleep apnea, and possibly cancer, addiction, and neurological decline. The question now isn't whether these drugs work, but how much of the excitement reflects genuine science and how much is hype built on preliminary findings.
GLP-1, or glucagon-like peptide-1, is a hormone your own body produces after you eat. It signals your pancreas to release insulin and tells your brain you're full. Ozempic and Wegovy are simply synthetic versions of this messenger. But here's what makes them so intriguing to researchers: GLP-1 receptors don't just sit in your gut. They're scattered throughout your heart, kidneys, liver, and brain—which opened the door to wondering whether these drugs could do vastly more than manage weight.
The cardiovascular findings are perhaps the most solid evidence. A trial of more than 17,000 people found that semaglutide reduced the risk of serious heart attacks and strokes by 20%, even in people without diabetes. That's not a marginal benefit. Similarly, semaglutide outperformed placebo in treating advanced liver disease in a trial of almost 1,200 patients. Tirzepatide, another GLP-1 drug sold as Mounjaro, significantly reduced the severity of sleep apnea, largely because the weight loss alone relieves pressure on the airways.
The cancer connection is more complicated. A study of 86,000 adults with obesity found that GLP-1 users had a 17% lower cancer risk—a finding that makes biological sense, since obesity itself is a risk factor for at least 13 cancers. Intriguingly, new data suggests GLP-1 users were less likely to experience cancer spread, possibly because these drugs carry anti-inflammatory effects that work independently of weight loss. But this work hasn't yet been verified by independent researchers, and no well-controlled clinical trials have definitively established the link.
Addiction treatment shows similarly mixed signals. An analysis of more than 1.3 million people found significantly lower rates of opioid overdose and alcohol intoxication among GLP-1 users. A randomized trial found semaglutide reduced drinking in people with alcohol use disorder, and early smoking-cessation trials look promising. These results make neurobiological sense: GLP-1 receptors concentrate in the brain's reward pathways, the same circuits that drive cravings for drugs, alcohol, and nicotine.
Endometriosis, which affects roughly 1 in 10 women of reproductive age, showed promise in a survey of 161 women, since GLP-1 receptors are present in reproductive tissue too. But again, there are no randomized trials.
The brain remains the haziest frontier. While there are sound biological reasons these drugs could combat neurodegeneration and depression, clinical evidence is conflicting. One study found that people with mild to moderate Alzheimer's disease taking liraglutide showed significantly less brain shrinkage in key regions. Yet larger trials have produced muddy results.
What emerges is a pattern: genuine promise, real early victories, but also a field moving faster than the evidence can keep up with. GLP-1 drugs have earned regulatory approval in new areas beyond weight loss, but many emerging applications remain one compelling study away from becoming headlines—and several headline-grabbing studies away from becoming standard medicine.